Logo

Silence Receives Notice of Allowance for US Patent Application

Aug 04, 2011
Premium

Silence Therapeutics said this week that it has received a notice of allowance from the US Patent and Trademark Office on a patent application covering its siRNA delivery technology.

According to Silence, the allowed claims relate to the company's AtuPlex technology. Specifically, they cover the proprietary lipid used in the delivery system. The company noted that the technology is being used in its phase I cancer drug Atu027, as well as certain other RNAi drug candidates.

Filed under

Gene Silencing/Gene Editing
USPTO
RNAi
Silence
Breaking News
The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.